Oct 29, 2026 7:00 am EDT Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Oct 21, 2026 7:00 am EDT Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
Oct 16, 2026 12:00 pm EDT Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Oct 15, 2026 4:00 pm EDT Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Sep 9, 2026 7:00 am EDT Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
Sep 2, 2026 7:00 am EDT Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Aug 19, 2026 4:01 pm EDT Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 6, 2026 7:00 am EDT Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update